Neurobehavioral Disorders Negative Allosteric Modulator Gets Fast Track Status for Social Anxiety Disorder Publish Date December 8, 2021 The Company will evaluate BNC210 in patients with SAD in the phase 2 PREVAIL trial.
Neurobehavioral Disorders Prescription Digital Therapeutic for Anxiety, Depression Treatment Launched Publish Date July 29, 2021 Ensemble is an AI-powered digital mental health coach app designed to address the symptoms of MDD or GAD.
Neurobehavioral Disorders Novel Combination Therapy for Major Depressive Disorder Gets Priority Review Publish Date May 3, 2021 AXS-05 consists of dextromethorphan, an NMDA receptor antagonist, and bupropion, a norepinephrine and dopamine reuptake inhibitor.